Vibativ ® treats patients with pneumonia and serious skin infections
Specialty pharmaceutical companies Tabuk Pharmaceutical Manufacturing Company a fully owned subsidiary of Astra Industrial Group and a leading pharmaceutical company in the Middle East and Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced the launch of Cumberland’s Vibativ ® (telavancin) injection in Saudi Arabia .
The announcement follows an agreement between the companies providing Tabuk with the exclusive rights to register and promote the product for patients in Saudi Arabia and other countries in the Middle East .
Vibativ is a patented, FDA-approved injectable anti-infective that can serve as a potentially life-saving treatment in patients with hospital-acquired and ventilator-associated pneumonia resulting from infections, including the flu and COVID-19. It is intravenously administered with once-daily dosing and does not require therapeutic drug monitoring, decreasing health care professionals’ exposure to the patient. It is designed to treat serious infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA ). Vibativ addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.
“Given the global concern about multidrug-resistant organisms, Vibativ is an important addition to our anti-infective portfolio and supports our mission to deliver unique health solutions and save the lives of people throughout the Middle Eastern countries we operate in,” said Ismail Shehadah , CEO of Tabuk. “We believe Vibativ will provide our physicians with a powerful new tool to battle multidrug-resistant infections and we are excited to launch the product in Saudi Arabia .”
